Outcomes for women with metastatic breast cancer can be improved by the effective use of biomarkers and genomic assays to quantify individual risk and guide treatment selection. This continuing medical education activity will enhance the ability of oncologists to develop optimal treatment plans while integrating the latest clinical evidence into practice, ultimately improving outcomes in MBC.
About OncoLink Contact OncoLink Privacy statement Disclaimer Link to OncoLink Home